Drug intelligence / Profile preview

gemcitabine + nab-paclitaxel + irinotecan

Development stage: Preclinical
Lead developer: Ipsen
Modality: Small Molecules
Administration: Intravenous

Overview

A combination chemotherapy regimen consisting of gemcitabine, nab-paclitaxel, and irinotecan. This specific three-drug combination is not standardized as a common regimen in the literature, though components are used in established pancreatic cancer treatment protocols. Gemcitabine is a nucleoside analog that interferes with DNA synthesis, nab-paclitaxel is an albumin-bound formulation of paclitaxel that stabilizes microtubules to prevent cell division, and irinotecan is a topoisomerase I inhibitor that prevents DNA unwinding and replication.

Targets

TUBB (Tubulin (alpha and beta subunits))TOP1 (DNA Topoisomerase I)DNA polymerase family

Beyond the preview

Go deeper on gemcitabine + nab-paclitaxel + irinotecan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gemcitabine + nab-paclitaxel + irinotecan.

Explore the full profile